Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations

Published: March 21, 2023

On this page

• Preamble
• Background
• Statement objective
• Methods
• Vaccine
• Evidence summary
  • Burden of disease
  • Evidence on safety, immunogenicity, and efficacy of PNEU-C-15 in pediatric populations
  • Evidence on concurrent administration of PNEU-C-15 with other routinely administered pediatric vaccines
• Recommendation
• Programmatic considerations table
• Research priorities
• List of abbreviations
• Acknowledgements
• Appendix A: Immunogenicity of PNEU-C-15 in pediatric populations
• References

Preamble

The National Advisory Committee on Immunization (NACI) is an External Advisory Body that provides the Public Health Agency of Canada (PHAC) with independent, ongoing, and timely medical, scientific, and public health advice in response to questions from PHAC relating to immunization.

In addition to burden of disease and vaccine characteristics, PHAC has expanded the mandate of NACI to include the systematic consideration of programmatic factors in developing evidence-based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels.

The additional factors to be systematically considered by NACI include economics, ethics, equity, feasibility, and acceptability. Not all NACI statements will require in-depth analyses of all programmatic factors. While systematic consideration of programmatic factors will be conducted using evidence-informed tools to identify distinct issues that could impact decision-making for recommendation development, only distinct issues identified as being specific to the vaccine or vaccine-preventable disease will be included.

This statement contains NACI's independent advice and recommendations, which are based upon the best current available scientific knowledge. This document is being disseminated for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph. Recommendations for use and other information set out herein may differ from that set out in the product monographs of the Canadian manufacturers of the vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

Background

On November 16, 2021, Health Canada authorized the use of a pneumococcal conjugate 15-valent vaccine, PNEU-C-15 (Vaxneuvance^®) ^{Footnote 1}, for adults 18 years of age and older. An age extension for the use of PNEU-C-15 in the pediatric population was authorized on July 8, 2022, under a priority review. This vaccine provides additional protection against two serotypes (22F and 33F) compared to the currently authorized pneumococcal conjugate 13-valent vaccine, PNEU-C-13 (Prevnar 13^®). PNEU-C-15 is currently indicated for active immunization of infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18th birthday) and adults 18 years of age and older for the prevention of invasive pneumococcal disease (IPD), including sepsis, meningitis, complicated pneumonia with or without empyema and bacteremia) caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F).

In Canada, current routine immunization programs for healthy infants include the use of pneumococcal conjugate (PNEU-C) vaccines provided either using a 3-dose schedule (at 2 months, 4 months, and 12 months of age) or a 4-dose schedule (at 2 months, 4 months and 6 months followed by a booster dose at 12 to 15 months of age). The routine immunization schedule for healthy low-risk children in the province of Quebec is a mixed schedule that includes the use of PNEU-C-10 at 2 and 4 months of age and the use of PNEU-C-13 at 12 months of age ^{Footnote 2}. For children at high risk, there is an additional dose of PNEU-C-10 at 6 months of age.

Among infants at high risk of IPD due to an underlying medical condition, the current routine immunization programs in all provinces and territories include receipt of PNEU-C vaccine in a 4 dose schedule (at 2 months, 4 months and 6 months followed by a booster dose at 12 to 15 months of age) as well as one dose of PNEU-P-23 vaccine at 24 months of age, at least 8 weeks after the last PNEU-C-13 vaccine dose ^{Footnote 3}. Children and adolescents at highest risk of IPD should also receive 1 booster dose of PNEU-P-23 vaccine ^{Footnote 3}.

In 2019, based on the childhood National Immunization Coverage Survey (cNICS), it was estimated that 84.4% of 2-year-old children in Canada had 3 or 4 doses of the pneumococcal vaccine ^{Footnote 4}. The current national vaccination coverage goal by 2025 is to have 95% of 2-year-old children immunized with 3 or 4 doses of the recommended pneumococcal vaccine(s) ^{Footnote 5}. Some but not all jurisdictions have already achieved the target.

Statement objective

The primary objective of this Interim Guidance is to review evidence on the safety and immunogenicity of PNEU-C-15 in the pediatric age group and to develop interim recommendations on its interchangeability with PNEU-C-13 for use in routine pediatric schedules as well as for children at high risk of IPD.

Methods

NACI reviewed key questions raised in consultation with the Canadian Immunization Committee and the Pneumococcal Working Group (PWG). These included the need for evidence pertaining to the burden of disease to be prevented in the target population(s), the safety, immunogenicity, efficacy, and effectiveness of the vaccine(s), vaccine schedules, and other aspects of the overall pediatric pneumococcal vaccine immunization strategy. A rapid evidence synthesis of clinical trials was performed by the NACI Secretariat and reviewed by the PWG on September 28, 2022.

NACI reviewed this evidence on October 3rd, 2022. The description of relevant considerations, rationale for specific decisions, and knowledge gaps are further described in the text. NACI voted on the interim recommendations on the use of PNEU-C-15 in pediatric populations on October 4, 2022, and recommendations were approved on December 12, 2022.

For additional information and NACI's current recommendations on the use of pneumococcal vaccines in children, please refer to the pneumococcal vaccine chapter in the Canadian Immunization Guide (CIG).

Further information on NACI's process and procedures is available elsewhere ^{Footnote 6 Footnote 7}.

Vaccine

In Canada, four preparations, PNEU-C-10 (Synflorix^TM) ^{Footnote 8}, PNEU-C-13 (PREVNAR^®13) ^{Footnote 9}, PNEU-C-15 (Vaxneuvance^®) ^{Footnote 1}, and PNEU-P-23 (Pneumovax^®23) ^{Footnote 10} of pneumococcal vaccine are currently authorized for use in persons less than 18 years of age (Table 1). All vaccines are indicated for the prevention of IPD caused by S. pneumoniae vaccine-contained serotypes.

Evidence summary

Burden of disease

IPD became nationally notifiable in 2000; before this time, only cases of pneumococcal meningitis were notifiable nationally. With the implementation of routine childhood pneumococcal immunization with PNEU-C-7 vaccine between 2002 and 2006, and PNEU-C-13 vaccine between 2010 and 2012, IPD incidence among children less than two years of age has decreased substantially from a peak of 73.0 cases per 100,000 population in 2003 to an average of 16.2 cases per 100,000 population between 2015 and 2019 ^{Footnote 11}.

Based on the data reported to Canadian Notifiable Disease Surveillance System (CNDSS), IPD due to PNEU-C-13 serotypes decreased in all pediatric age groups between 2011 and 2020 ^{Footnote 12}. During this period, the decrease ranged from approximately 42% in the 2- to 4-year-old age group to approximately 20% in other age groups. IPD due to serotype 3 deceased from 6.8% in 2011 to 4.9% on 2020 among children less than 2 years old, while it increased from 11.1% in 2011 to 15.8% in 2020 among children 2 to 4 years old. At the same time, IPD cases due to the two additional serotypes 22F and 33F included in the newly authorized PNEU-C-15 vaccine increased from 7.9% to 15.9% in the less than 2 year old age group, and from 11.8% to 18.4% in the 2- to 4-year-old age group ^{Footnote 12}.

The proportion of serotypes 22F and 33F in children 0 to 4 years of age increased from 9.6% in 2011 to 16.7% in 2020. In the 5- to 17-year-old age group, the proportion of these serotypes increased from 5.4% in 2011 to 20.2% in 2019, before decreasing back to 5.0% in 2020. The proportion of serotype 3 in children 0 to 4 years old stayed relatively stable (8.7% in 2011, 8.3% in 2020) and for those 5 to 17 years old, it increased from 6.7% in 2011 to 20.0% in 2020. Data for 2020 may not be reflective of the actual trend as the COVID-19 pandemic may have impacted disease incidence in all age groups.

Serotype 22F was more commonly (11.7%) reported in 2020 among IPD cases in children less than 5 years of age than serotype 33F (5.0%). In 2020, serotypes 3, 22F, 10A, 19A and 15B/C were the most common causes of pediatric IPD, representing approximately half of the cases. Serotype 3 alone caused 11.3% of all pediatric IPD cases in 2020, it was least prevalent (4.9%) in the less than 2 year old age group.

Evidence on safety, immunogenicity, and efficacy of PNEU-C-15 in pediatric populations

NACI reviewed the evidence on safety, and immunogenicity of PNEU-C-15 vaccine from eight Phase 2/3 clinical trials ^{Footnote 13 Footnote 14 Footnote 15 Footnote 16 Footnote 17 Footnote 18 Footnote 19 Footnote 20} which included a range of pediatric populations and which used different vaccine schedules (Table 2). An additional trial, V114-022 ^{Footnote 21}, provided immunogenicity and safety data following the immunization of hematopoietic stem cell transplant (HSCT) recipients.

Since there are currently no efficacy or effectiveness data available for PNEU-C-15 vaccine for any pediatric indication, the basis for regulatory authorization was the demonstration of comparable safety and immunogenicity (non-inferiority for serotypes common to PNEU-C-13 and superiority for two additional serotypes) in relation to PNEU-C-13 vaccine.

Immunogenicity summary

NACI reviewed the available evidence on immunogenicity of PNEU-C-15 in mixed PNEU-C-15 and PNEU-C-13 regimens (pertaining to routine immunization programs for infants and children without IPD risk factors) as well as evidence on immunogenicity of PNEU-C-15 in high-risk pediatric populations. Additional details on immunogenicity findings that were reported in PNEU-C-15 clinical trials in pediatric populations are provided in Appendix A.

Immunogenicity of PNEU-C-15 in mixed PNEU-C-15 and PNEU-C-13 regimens

To address the policy question of PNEU-C-15 interchangeability with PNEU-C-13, NACI reviewed the evidence on immunogenicity in the mixed PNEU-C-15 and PNEU-C-13 regimen (interchangeability trial, V114-027 ^{Footnote 17}). Overall, available evidence suggests that the vaccines had comparable immune responses for the 13 shared serotypes. The immune response to the two additional serotypes (22F, 33F) and for serotypes 3 was higher after PNEU-C-15 compared to PNEU-C-13. In one study, V114-029 immune responses to serotypes 22F, 33F and 3 were superior following PNEU-C-15 compared to PNEU-C-13 (Appendix A).

In the V114-027 trial, 900 healthy participants 40 to 90 days of age were randomized to one of five groups (n=180 per group) to receive a complete four dose series with PNEU-C-13, PNEU-C-15 or mixed regimen initiated with one, two or three doses of PNEU-C-13 and continued with PNEU-C-15.

When assessed by serotype-specific IgG GMCs and IgG GMC ratios, a mixed regimen of PNEU-C-15 and PNEU-C-13 30 days after dose 4 (administered at approximately 12 to 15 months of age) elicited generally comparable immune responses to a complete 4-dose regimen of PNEU-C-13 for the 13 shared serotypes.

At 30 days following the receipt of the third dose, serotype-specific immune responses for the 13 shared serotypes were generally comparable across intervention groups as assessed by the proportions of participants meeting the pre-specified IgG seroresponse threshold value of ≥0.35 µg/mL and IgG GMCs. In contrast, serotype-specific immune responses for unique serotypes 22F and 33F were higher in PNEU-C-15 vaccine recipients. Immune responses for serotype 33F increased incrementally with additional PNEU-C-15 doses received in the infant series (as assessed by response rates and IgG GMCs) while they remained unchanged for serotype 22F.

Immunogenicity of PNEU-C-15 in pediatric populations at high-risk of IPD

To address the policy question of PNEU-C-15 interchangeability with the currently recommended PNEU-C-13 for children at increased risk of IPD, NACI reviewed the evidence of immunogenicity data from two studies. Overall, in high-risk populations, PNEU-C-15 had comparable immunogenicity to PNEU-C-13 for shared serotypes.

In the V114-23 ^{Footnote 14} and V114-030 ^{Footnote 19} trials children 5-17 years old living with sickle cell disease and children 6-17 years old living with HIV, respectively, were randomized to receive either PNEU-C-15 or PNEU-C-13 and PNEU-C-15+PNEU-P-23 or PNEU-C-13+PNEU-P-23. When assessed by serotype-specific IgG GMC and OPA GMT at 30 days post vaccination, immune responses were generally similar between the intervention and comparator groups for the shared serotypes and higher for the PNEU-C-15 unique serotypes, 22F and 33F. At 30 days following the administration of PNEU-P-23 in V114-030, IgG GMC and OPA GMTs were numerically similar for all 13 shared and the two unique serotypes.

Safety summary

In all studies, the evidence on safety showed that PNEU-C-15 is safe in healthy children and in select special populations. Safety following immunization with PNEU-C-15 vaccine was measured in all Phase 2/3 clinical trials that included healthy children ^{Footnote 13 Footnote 15 Footnote 16 Footnote 17 Footnote 18 Footnote 20} (six studies), children with sickle cell disease ^{Footnote 14} (one study) and HIV infection^{Footnote 19} (one study). The measured safety endpoints included the proportion of participants with solicited local and systemic adverse events (AEs) 1 to 14 days post vaccination, maximum body temperature measurements (1–7 days post vaccination) and serious adverse events (SAEs), up to 6 months following vaccination.

In the pivotal study ^{Footnote 16}, in which PNEU-C-15 was administered as a 3-dose series (V114-025), the safety profile was found to be generally comparable to PNEU-C-13 ^{Footnote 16} (Table 9, Appendix A). An integrated safety analysis ^{Footnote 1} was conducted for healthy infants (studies 025 ^{Footnote 16}, 027 ^{Footnote 17}, 029 ^{Footnote 18}, and 031 ^{Footnote 20}) in the final safety database including 3,592 participants receiving at least one dose of PNEU-C-15 and 2,062 receiving at least one dose of PNEU-C-13.

The proportions of participants with local and systemic AEs (solicited and unsolicited) after each dose in the primary series, after the toddler booster dose, and after any dose were generally comparable in both intervention groups. In infants, the most frequently reported AEs following each dose were irritability (45.7%), somnolence (21.8%), injection-site pain (21%), decreased appetite (19.4%) and other injection-site reactions (erythema, swelling, induration; all less than 22%) (Table 10, Appendix A). The majority of participants who received PNEU-C-15 reported maximum body temperature measurements of less than 38.0 °C, with a temperature distribution that was comparable between intervention groups. Of the participants with a maximum body temperature higher than 38.0 °C, the majority had a maximum body temperature below 39.0 °C.

SAEs were reported for up to 5.5% of participants following each dose of PNEU-C-15 and up to 4.7% of participants following each dose of PNEU-C-13. While the majority of SAEs were deemed to be not vaccine-related, there were three vaccine-related SAEs reported in 2 participants in the PNEU-C-15 group and 1 participant in the PNEU-C-13 group (all were pyrexia requiring hospitalization). There were 4 deaths reported among study participants, of which none were considered to be related to the study interventions. The safety profile of mixed dosing regimens with PNEU-C-15 was comparable to complete PNEU-C-13 and PNEU-C-15.

In children with sickle cell disease or living with HIV infection ^{Footnote 14 Footnote 19}, the safety profile was generally consistent with the safety profile in healthy children.

Evidence on concurrent administration of PNEU-C-15 with other routinely administered pediatric vaccines

Concurrent administration of PNEU-C-15 with other routinely administered pediatric vaccines was assessed in three clinical trials (protocols 025 ^{Footnote 16}, 027 ^{Footnote 17} and 029 ^{Footnote 18}) involving over 1,700 infants and toddlers ^{Footnote 16 Footnote 17 Footnote 18}, In addition to PNEU-C-15, study participants also received diphtheria, tetanus, pertussis, poliomyelitis (serotypes 1, 2 and 3), hepatitis A, hepatitis B, Haemophilus influenzae type b, measles, mumps, rubella, varicella, and rotavirus vaccine, either as monovalent or combination vaccines within the primary infant series or with the toddler booster dose.

Immune responses to all antigens provided concomitantly with PNEU-C-15 met non-inferiority criteria as assessed by the individual antigen-specific response rates (for the combination and monovalent vaccines) or GMT (rotavirus vaccine) at 30 days following vaccine administration. Overall, all studies reviewed by NACI showed that PNEU-C-15 can be administered concurrently with other routine pediatric vaccines.

Recommendation

Following the review of key evidence summarized above, NACI makes the following interim recommendation for public health program level decision-making.

Please see Table 3 for a more detailed explanation of strength of NACI recommendations and grade of the body of evidence.

NACI recommends that PNEU-C-15 vaccine may be used interchangeably with PNEU-C-13 vaccine in children less than 18 years of age. A pneumococcal vaccine series may be started or completed with either vaccine. (Discretionary NACI recommendation)

Summary of evidence, rationale, and additional considerations:

• There are currently no data on efficacy or effectiveness that would allow a comparative assessment of clinical outcomes of vaccination with PNEU-C-15 versus PNEU-C-13.
• In immunogenicity studies, PNEU-C-15 has shown to have comparable immune responses to PNEU-C-13 for shared serotypes and higher immune responses for unique serotypes as measured by seroresponse rates, total antibody levels, and functional antibody levels.
• PNEU-C-15 has been shown to have comparable safety profile to PNEU-C-13 when given as a single vaccine type series, when used in mixed PNEU-C-15/PNEU-C-13 schedules and when concurrently administered with other routine pediatric vaccines.
• PNEU-C-15 has the potential to prevent up to about 20% more cases of IPD in children 4 years of age and younger based on CNDSS epidemiology data.
• Introduction of PNEU-C-15 programs into routine schedules may provide additional benefit through direct effects on non-invasive pneumococcal infections (e.g., acute otitis media [AOM], community acquired pneumonia [CAP]). In addition, further indirect benefits of broadened protection could be expected in adults over time, as suggested by the reduction of IPD burden in older adults following the introduction of routine PNEU-C pediatric programs.
• Although NACI has not conducted any cost-effectiveness analysis, if product costs were equivalent, then PNEU-C-15 could potentially provide greater health gains and lead to reduced healthcare utilization compared to PNEU-C-13 due to the protection anticipated from two additional serotypes.
• NACI's recommendations for the use of PNEU-P-23 in combination with PNEU-C-13 or PNEU-C-15 for high-risk children remain unchanged.

Programmatic considerations table

Additional information on PNEU-C-15 is contained within the product monograph available through Health Canada's Drug Product Database (DPD).

In general, vaccines with increased number of antigens will likely broaden protection not only in terms of IPD, but also non-invasive pneumococcal disease which may include AOM, CAP and other pneumococcal infections. For example, in one European study ^{Footnote 22}, among children aged 6–36 months with clinically diagnosed AOM, 8% of infections were caused by PNEU-C-15 unique serotypes.

Given the significant number of AOM and CAP infections, even small percent reductions in cases have the potential to significantly reduce the overall pneumococcal disease burden. In addition, further indirect benefits of broadened protection could be expected over time in adults, as suggested by the reduction of IPD burden in older adults following the introduction of previous routine PNEU-C pediatric programs.

Research priorities

• Determining the direct (children) and indirect (adults) impact of PNEU-C-15 programs on the burden of disease (AOM, pneumonia, IPD) in individuals with and without risk factors for invasive disease in the context of different vaccines and vaccine schedules used in Canada.
• Determining the vaccine effectiveness of PNEU-C-15 in healthy and in immunocompromised pediatric population.
• Determining the duration of immunity for PNEU-C-15 only and in mixed schedule programs.
• Assessing the cost effectiveness of PNEU-C-15 in pediatric population.

List of abbreviations

AEFI

Adverse event following immunization

AOM

Acute otitis media

CAP

Community acquired pneumonia

CI

Confidence interval

CIC

Canadian Immunization Committee

GMC

Geometric mean concentration

HIV

Human Immunodeficiency Virus

IgG

Immunoglobulin G

IPD

Invasive pneumococcal disease

NACI

National Advisory Committee on Immunization

NOC

Notice of Compliance

PHAC

Public Health Agency of Canada

PNEU-C-13

13-valent conjugate pneumococcal vaccine

PNEU-C-15

15-valent conjugate pneumococcal vaccine

PWG

Pneumococcal working group

ST

Serotype

Acknowledgements

This statement was prepared by: K Hildebrand, O Baclic, R Pless, A Wierzbowski and E Wong on behalf of the NACI Pneumococcal Working Group and was approved by NACI.

NACI gratefully acknowledges the contribution of: A Li, A Golden, W Demczuk, A Griffith, I Martin, M Salvadori, C Tremblay, M Tunis, and J Zafack.

NACI Pneumococcal Working Group

NACI Pneumococcal Working Group Members: K Hildebrand (Chair), J Papenburg, P De Wals, N Brousseau, J Bettinger, D Fisman, J Kellner, S Rechner, G Tyrrell, A McGeer, S Nasreen, and M Kobayashi (Centers for Disease Control and Prevention, US).

Ex-officio representatives: M Knight (First Nations and Inuit Health Branch, ISC), G Coleman (Biologic and Radiopharmaceutical Drugs Directorate, HC), A Y Li (VPD Surveillance), I Martin (National Microbiology Laboratory) and G Metz (Vaccine Safety).

PHAC participants: E Wong, A Wierzbowski, R Pless, O Baclic, M Tunis, A Stevens, N Islam, A Tuite, MW Yeung, A Killikelly, Robert MacTavish, Fiann Crane, F Khan, M Hersi, A Simmons, and C Tremblay.

NACI

NACI members: S Deeks (Chair), R Harrison (Vice-Chair), M Andrew, J Bettinger, N Brousseau, H Decaluwe, P De Wals, E Dubé, V Dubey, K Hildebrand, K Klein, M O'Driscoll, J Papenburg, A Pham-Huy, B Sander, and S Wilson.

Liaison representatives: L Bill/ M Nowgesic (Canadian Indigenous Nurses Association), LM Bucci (Canadian Public Health Association), E Castillo (Society of Obstetricians and Gynaecologists of Canada), J Comeau (Association of Medical Microbiology and Infectious Disease Control), M Osmack (Indigenous Physicians Association of Canada), J Potter (College of Family Physicians of Canada), M Lavoie (Council of Chief Medical Officers of Health), D Moore (Canadian Paediatric Society), M Naus (Canadian Immunization Committee), and A Ung (Canadian Pharmacists Association).

Former liaison representatives: L Dupuis (Canadian Nurses Association), D Fell (Canadian Association for Immunization Research and Evaluation), J Hu (College of Family Physicians of Canada)

Ex-officio representatives: V Beswick-Escanlar (National Defence and the Canadian Armed Forces), E Henry (Centre for Immunization and Respiratory Infectious Diseases (CIRID), PHAC), M Lacroix (Public Health Ethics Consultative Group, PHAC), C Pham (Biologic and Radiopharmaceutical Drugs Directorate, Health Canada), S Ogunnaike-Cooke (CIRID, PHAC), P Fandja (Marketed Health Products Directorate, HC), M Routledge (National Microbiology Laboratory, PHAC), and T Wong (First Nations and Inuit Health Branch, Indigenous Services Canada).

Former ex-officio representatives: C Lourenco (Biologic and Radiopharmaceutical Drugs Directorate, Health Canada), K Robinson (Marketed Health Products Directorate, HC)

Appendix A: Immunogenicity of PNEU-C-15 in pediatric populations

Immunogenicity following immunization with PNEU-C-15 was reported in seven Phase 2/3 clinical trials that included healthy children (five studies ^{Footnote 13 Footnote 15 Footnote 16 Footnote 17 Footnote 18}), children with sickle cell disease (one study ^{Footnote 14}) and HIV infection (one study ^{Footnote 19}). The measured outcomes included serotype-specific immunoglobulin G (IgG) responses (reported as the proportion of study participants meeting the IgG threshold value of ≥0.35 μg/mL), geometric mean concentrations (GMC) and opsonophagocytic activity (OPA) geometric mean titres (GMT) at 30 days after dose administration.

In the pivotal double-blind clinical trial V114-025 ^{Footnote 16}, immunogenicity was measured in healthy infants aged 2 to 15 months who were vaccinated with PNEU-C-13 (n=591) or PNEU-C-15 (n=588) at 2, 4 and 11–15 months of age. One month following dose 3, non-inferior seroresponse (based on the lower bound of the 95% CI for the percentage point difference being greater than -10 points) was observed for all 13 shared serotypes, and higher immune responses were observed for the two PNEU-C-15 unique serotypes (Table 5, Appendix A).

Similarly, at one month post dose 3, IgG GMC values were found to be non-inferior (based on the lower bound of the 2-sided 95% CI for the GMC ratio being >0.5) for all 13 shared serotypes and superior for the PNEU-C-15 unique serotypes (Table 6, Appendix A). Of note, although numerically similar, all observed GMC values were generally lower for PNEU-C-15 compared to PNEU-C-13, except for ST3. When assessed by OPA GMT, functional antibodies were found to be generally comparable for all shared serotypes.

In another pivotal double-blind clinical trial (V114-029 ^{Footnote 18}) immunogenicity was assessed in over 1,700 healthy infants 6 to 12 weeks of age using a four dose schedule (vaccine provided at 2, 4, 6 and 12-15 months of age). One month following dose 4, seroresponse rates after PNEU-C-15 administration were found to be non-inferior for all 13 shared serotypes and superior for the two unique types compared to PNEU-C-13 (Table 7, Appendix A).

In the V114-029 trial, measurement of serotype-specific IgG GMC at 30 days following the 3 dose primary series also demonstrated non-inferiority to PNEU-C-13 for the majority of serotypes, with a response to only one serotype (6A) not meeting the non-inferiority criteria by a small margin (the lower bound of the 2-sided 95% CI for the GMC ratio being 0.48) (Table 8, Appendix A). In addition, 30 days following both dose 3 and dose 4, superiority was demonstrated for the two PNEU-C-15 unique serotypes as well as ST3. Serotype-specific OPA GMT at 30 days following the 3 dose primary series and toddler booster dose were reported to be numerically similar to PNEU-C-13 for the shared serotypes and higher for the unique serotypes.

Clinical trial data on PNEU-C-15 in children

References